Table 1.
Clinical details of healthy donors and patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.
| Healthy donors (1) | Rheumatoid arthritis | Healthy donors (2) | Psoriatic arthritis | Axial spondyloarthritis | |
|---|---|---|---|---|---|
| Clinical parameters | |||||
| Women/men (n/n) | 39/11 (50) | 158/42 (200) | 17/33 (50) | 34/46 (80) | 45/105 (150) |
| Age (years) | 46.06 ± 10.08 | 46.94 ± 7.94 | 43.85 ± 11.15 | 45.82 ± 9.99 | 44.63 ± 11.93 |
| Disease duration (years) | – | 10.00 ± 9.43 | – | 8.43 ± 7.81 | 14.28 ± 12.86b,c |
| RF (n +/n–) | – | 140/60 | – | – | – |
| ACPAs (n +/n–) | – | 151/49 | – | – | – |
| DAS28 | – | 4.54 ± 1.57 | – | 3.87 ± 1.74 | – |
| BASDAI | – | – | – | – | 4.32 ± 2.56 |
| BASMI | – | – | – | – | 3.09 ± 1.73 |
| Smoking (yes/no) | 7/43 | 70/130a | 16/84 | 25/55 | 68/82a,b,c |
| BMI (kg/m²) | 24.66 ± 4.76 | 26.95 ± 5.13a | 25.06 ± 3.93 | 28.29 ± 3.87a | 26.51 ± 4.31c |
| Laboratory parameters | |||||
| Glucose (mg/dl) | 81.15 ± 8.40 | 85.07 ± 23.71 | 86.85 ± 15.08 | 91.72 ± 23.14 | 85.54 ± 16.09c |
| Insulin (mg/dl) | 6.30 ± 3.35 | 9.15 ± 6.26a | 7.56 ± 5.23 | 11.71 ± 7.80a,b | 7.83 ± 5.26b,c |
| Cholesterol (mg/dl) | 177.43 ± 32.44 | 198.34 ± 36.22 | 196.44 ± 28.68 | 188.76 ± 38.06 | 188.76 ± 38.06b |
| HDL-cholesterol (mg/dl) | 56.98 ± 14.41 | 57.24 ± 19.11 | 56.34 ± 15.05 | 50.00 ± 12.57a,b | 53.06 ± 15.70b |
| LDL-cholesterol (mg/dl) | 115.54 ± 29.04 | 119.83 ± 31.43 | 119.96 ± 25.45 | 130.64 ± 26.96a,b | 114.73 ± 30.90c |
| Apolipoprotein A (mg/dl) | 150.65 ± 23.32 | 146.64 ± 30.05 | 149.95 ± 25.11 | 148.00 ± 27.51 | 138.35 ± 23.43a,b,c |
| Apolipoprotein B (mg/dl) | 87.45 ± 22.88 | 84.76 ± 20.72 | 90.38 ± 24.87 | 97.97 ± 18.64b | 90.82 ± 25.02b,c |
| Triglycerides (mg/dl) | 89.64 ± 43.36 | 99.27 ± 47.67 | 97.54 ± 43.43 | 106.82 ± 46.32 | 104.24 ± 55.01 |
| ESR (mm/1 h) | 7.55 ± 4.74 | 22.94 ± 17.35a | 6.62 ± 5.12 | 19.07 ± 14.57a | 16.52 ± 17.57a |
| CRP (mg/dl) | 1.40 ± 1.75 | 12.70 ± 26.56a | 1.60 ± 2.04 | 14.13 ± 20.42a | 11.38 ± 18.53a |
| Treatments | |||||
| NSAIDs (yes/no) | – | 162/38 | – | 64/16 | 138/12b |
| Corticosteroids (yes/no) | – | 140/60 | – | 32/48b | 4/145b,c |
| Antimalarial (yes/no) | – | 33/167 | – | – | – |
| Methotrexate (yes/no) | – | 110/90 | – | 31/49b | 7/143b,c |
| Leflunomide (yes/no) | – | 81/119 | – | 17/63b | – |
Values are mean ± SD, unless stated otherwise.
HDs(1), healthy donors cohort, age and sex-matched with rheumatoid arthritis group; HDs(2), healthy donors cohort, age and sex-matched with psoriatic arthritis and ankylosing spondylitis cohorts.
Significant differences versus their corresponding HD group (p < 0.05).
Significant differences versus RA (p < 0.05).
Significant differences versus PsA (p < 0.05).
ACPAs, anti-citrullinated protein antibodies; BASDAI, Bath ankylosing spondylitis disease activity index; BMI, body mass index; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor.